Replimune Group, Inc. Share Price
NASDAQ: REPLReplimune Group, Inc. Stock Performance
Open N/A | Prev. Close N/A | Circuit Range N/A |
Day Range N/A | Year Range N/A | Volume N/A |
Average Traded N/A |
Replimune Group, Inc. Share Price Chart
Replimune Group, Inc. Stock Fundamentals & Key Indicators
Market Cap N/A | PE Ratio (TTM) N/A | Dividend Yield N/A |
EPS (TTM) $-3.07 | Revenue (TTM) N/A | Return On Equity (TTM) N/A |
Profit Margin N/A | Debt to Equity 0.15 | Quarterly Earnings Growth YoY N/A |
About Replimune Group, Inc.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Replimune Group, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|
REPL Share Price FAQs
What is Replimune Group, Inc. share price today?
What is the 52 week high and 52 week low of Replimune Group, Inc. stock?
Can I buy REPL shares in India?